Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lupus Erythematosus, Discoid Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

NCT00708916
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
CC-10004
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

NCT04781816
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Cooper City, Florida • Charlotte, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

NCT00001680
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Thalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers

NCT02034344
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
Interventions
Skin biopsy, Blood collection, Urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 21, 2026, 10:18 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

NCT00797784
View directory record Official record
Conditions
Discoid Lupus Erythematosus (DLE)
Interventions
etanercept(Enbrel®)
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

NCT01300208
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
CC-11050, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Jul 21, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

NCT01597050
View directory record Official record
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
R932333, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Early Phase 1 Interventional

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

NCT03159936
View directory record Official record
Conditions
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Interventions
Tofacitinib citrate
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Jul 21, 2026, 10:18 PM EDT
Enrolling by invitation Phase 3 Interventional

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

NCT03958955
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Skokie, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Recruiting Phase 4 Interventional

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Upland, California • DeBary, Florida • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SC Milatuzumab in SLE

NCT01845740
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions
milatuzumab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

NCT04908280
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Withdrawn Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

NCT03866317
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Secukinumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 1 Interventional Results available

Autologous Polyclonal Tregs for Lupus

NCT02428309
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Jul 21, 2026, 10:18 PM EDT
Withdrawn Phase 2 Interventional

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

NCT00308204
View directory record Official record
Conditions
Discoid Lupus Erthematosus of the Scalp
Interventions
Raptiva
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

NCT05591222
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Placebo, Daxdilimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
North Little Rock, Arkansas • Beverly Hills, California • Fremont, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

NCT01466725
View directory record Official record
Conditions
Discoid Lupus
Interventions
CC-930, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 21, 2026, 10:18 PM EDT